Abstract | Introduction: Previous studies suggested that sevelamer carbonate is well tolerated with a favorable efficacy and safety profile in both dialysis and nondialysis patients in Europe; however, the efficacy remains controversial, and few studies have examined sevelamer carbonate therapy in other ethnic nondialysis CKD patients. This study assessed the efficacy and safety of sevelamer carbonate in Chinese nondialysis CKD patients with hyperphosphatemia. Methods: The multicenter, randomized, double-blind, parallel-group, placebo-controlled, and phase 3 clinical trial enrolled 202 Chinese nondialysis CKD patients with serum phosphorus ≥1.78 mmol/L. Patients were randomly assigned 1:1 to receive sevelamer carbonate (2.4-12 g per day) or placebo for 8 weeks. The primary outcome was the change in serum phosphorous between baseline and week 8. Results: Conclusion:
|
Authors | Wei Chen, Hua-Feng Liu, Qin-Kai Chen, Ming-Hui Zhao, Xiao-Nong Chen, Hong Liu, Jian-Xin Wan, Shao-Mei Li, Meng-Hua Chen, Chun Dai, Hong-Bin Shi, Jia-Li Wei, Hong-Wen Zhao, Li-Hua Wang, Gang Long, Wan-Hong Lu, Ying Tang, Jun-Wei Yang, Li-Ying Cao, Dong-Xing Tang, Yu-Qiong Yang, Xue-Qing Yu |
Journal | Kidney diseases (Basel, Switzerland)
(Kidney Dis (Basel))
Vol. 9
Issue 2
Pg. 82-93
(Apr 2023)
ISSN: 2296-9381 [Print] Switzerland |
PMID | 37065610
(Publication Type: Journal Article)
|
Copyright | Copyright © 2022 by The Author(s). Published by S. Karger AG, Basel. |
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|